['secondary hyperparathyroidism']
['khk7580', 'krn1493']

        Inclusion Criteria:

          -  Personally submitted written voluntary informed consent to participate in the study

          -  Stable chronic renal disease treated with hemodialysis 3 times weekly for at least 12
             weeks before screening

          -  Mean intact PTH level of > 240 pg/ml at screening, at 2 weeks and 1 week before the
             start of study treatment

        Exclusion Criteria:

          -  Treatment with cinacalcet hydrochloride within 2 weeks before screening;

          -  Change in dose or dosing regimen of an activated vitamin D drug or its derivative,
             phosphate binder, or calcium preparation within 2 weeks before screening; or start of
             treatment with such drugs within 2 weeks before screening;

          -  Parathyroidectomy and/or parathyroid intervention within 24 weeks before screening;

          -  Severe heart disease;

          -  Severe hepatic dysfunction;

          -  Uncontrolled hypertension and/or diabetes;

          -  Treatment with an investigational product (drug or medical device) in a clinical study
             or any study equivalent to clinical study within 12 weeks before screening;

          -  Primary hyperparathyroidism;

          -  Other conditions unfit for participation in this study at the discretion of the
             investigator or subinvestigator.
      